Insights & news

European Commission Guidance on Brexit and EU Rules in Field of Clinical Trials

  • 11/05/2020
  • Articles

On 7 May 2020, the European Commission published an updated version of its notice on the “withdrawal of the United Kingdom and EU rules in the field of clinical trials” (see, attached copy; the Revised Notice).
 
Initially published on 6 September 2018, the Revised Notice has been updated to reflect the UK’s withdrawal from the EU since 1 February 2020 and the effect of the Withdrawal Agreement (i.e., the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, OJ L 29, 31.1.2020, p. 7). The Withdrawal Agreement provides for a transition period ending on 31 December 2020 during which the EU and the UK will negotiate an agreement on a new partnership. During this period, EU law continues to apply in its entirety to and in the UK, subject to some limited exceptions.
 
The Revised Notice reminds clinical trial sponsors of the legal situation after the end of the transition period as regards (i) the supply of investigational medicinal products (IMPs); (ii) establishment requirements; and (iii) the submission of clinical trial information to the EU clinical trials database EudraCT. It stresses that clinical trial sponsors should pay particular attention to (i) ensuring that the sponsor or its legal representative is established in the EU; and (ii) adapting distribution channels to take importation requirements into account.
 
Furthermore, the Revised Notice clarifies the application of Article 41(1)(a) of the Withdrawal Agreement to IMPs. This Article 41(1)(a) provides that “[a]ny good that was lawfully placed on the market in the Union or the United Kingdom before the end of the transition period may be further made available on the market of the Union or of the United Kingdom and circulate between these two markets until it reaches its end-user”.
 
Finally, the Revised Notice explains the rules applicable to Northern Ireland after the end of the transition period.

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 02/06/2020
    • Articles

    Italian Competition Authority Approves Scheme for Distribution of Surgical Masks

    On 1 June 2020, the Italian competition authority (“L’Autorità Garante della Concorrenza e del Mercato”) authorised a scheme that would allow disposable surgical masks to be distributed and sold in pharmacies and health product retail outlets (see, attached press release). It did so at the request of the two principal Italian associations of pharmaceutical wholesalers. Under the scheme, the wholesalers and associations of pharmacists and health product retailers acquire the masks in a joint procurement procedure. The masks are then allocated among the wholesalers at a uniform price per unit that was agreed upon with the suppliers. The scheme will last until 30 June 2020. The competition authority approved the scheme because it solves an urgent and wide-ranging health problem and is limited in time. It thus applied for the first time the principles of its guidance of 22 April 2020 regarding cooperation agreements designed to ensure the distribution of scarce essential goods and services, including health products and food. The competition authority’s approach is in line with the views expressed by the European Commission and competition authorities around Europe to address the problems resulting from the Covid-19 pandemic (see e.g., Van Bael & Bellis Life Sciences News Alert of 9 April 2020 and of 26 May 2020). Not coincidentally, the competition authority indicates that it obtained counsel from the European Commission.

    Read more
    • 29/05/2020
    • Articles

    European Commission Presents EU4Health Programme

    On 28 May 2020 the European Commission (the Commission) presented details of its new, stand-alone EU4Health Programme, a proposal to commit considerable EU resources to health during the 2021-2027 period (EU4Health). The budget which the Commission proposes to earmark for EU4Health, EUR 9.4 billion, reflects a more than 20-fold increase over the funds previously dedicated to this policy area (EUR 413 million). The Commission first made its plan public as part of the presentation of ‘Next Generation EU’, a EURO 750 billion recovery plan to be embedded in and added to the long term overall EU budget for the 2021-2027 period (see, Van Bael & Bellis Life Sciences News Alert, 28 May 2020).

    Read more
    • 28/05/2020
    • Articles

    Next Generation EU - European Commission Proposes Significant Funding and Expanded EU Health Programme

    The European Commission (the Commission) published on 27 May 2020 its proposal for a major recovery plan and put forward a new EUR 750 billion recovery instrument called ‘Next Generation EU’ that would be embedded in and added to the long term EU budget (itself worth some EUR 1,100 billion between 2021 and 2027). The money from Next Generation EU would be available to the Member States in the form of both grants (EUR 500 billion) and loans (EUR 250 billion). The focus of the recovery plan is the green and digital transition but the plan also has a substantial health component, at times intertwined with green and digital aspects.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *